CompanyGraph
Makes the blood cancer drug JAKAFI, which every rival JAK inhibitor must prove itself against to win approval.
- Depends onMidstream position: 3 outgoing, 3 incoming connections
- ScaleMarket cap is above the global median
- FinancialsAltman Z-Score: safe zone
- Interpretations7 currently firing — 1 · 6
What this company is and how it runs — written from structure, not news.
Incyte makes a drug called JAKAFI that blocks the protein driving myelofibrosis, a bone marrow disease that had no approved treatment before JAKAFI reached patients — which meant its clinical trial data became the benchmark that regulators require every subsequent JAK inhibitor to match in head-to-head studies. Because challengers must prove they are at least as effective as JAKAFI specifically, Incyte's own historical data is now written into the approval pathway of every competitor trying to enter the same indication. Even when a competitor clears that regulatory bar, an oncologist switching a stable patient must restart dose escalation from scratch, rerun blood monitoring protocols, and navigate a separate prior authorization process at a new specialty pharmacy, which gives prescribers a concrete reason to stay put. The one constraint Incyte cannot buy its way around is patient enrollment: myelofibrosis, polycythemia vera, and graft-versus-host disease each draw from a small, fixed global population, so no amount of capital can shorten the clinical timelines needed to establish the next approved indication — and a serious safety signal in any of those populations would simultaneously destroy the reference-standard position, dissolve the switching friction, and cut off the revenue that funds the next trial.
How does this company make money?
The company earns money primarily from selling JAKAFI through specialty distributors that supply oncology practices in the United States. Outside the US, Novartis sells the same drug under the name Jakavi and pays royalties back to the company on those sales. The company also sells OPZELURA, a dermatology product, through its own separate distribution channel. It receives additional milestone payments and royalties from a partnership with MorphoSys on a drug called tafasitamab.
What makes this company hard to replace?
Switching a patient from JAKAFI to a different JAK inhibitor is not simple. Each JAK inhibitor has its own potency level and side effect pattern, so the oncologist must restart the dose-escalation process from scratch. The patient needs new rounds of blood monitoring to make sure the new drug is working safely. The specialty pharmacy that handles the new drug has its own prior authorization process, which takes time and administrative effort to complete — separate from whatever was already in place for JAKAFI.
What limits this company?
The company cannot simply spend more money to grow faster. Expanding into new blood cancers — like polycythemia vera or graft-versus-host disease — requires running clinical trials, and those trials can only enroll patients who actually have these rare conditions. There are only so many such patients in the world, so no amount of capital can speed up the clock.
What does this company depend on?
The company relies on manufacturers that produce the active chemical ingredient in ruxolitinib and other JAK inhibitors. It depends on FDA approval to sell JAKAFI in the US for myelofibrosis and polycythemia vera. It needs specialty pharmacy distribution networks to get the drug to oncology practices. It depends on clinical trial sites that can find and enroll patients with rare hematologic diseases. And it depends on patent protection covering its JAK inhibitor chemical structures, which runs through roughly 2027 to 2030.
Who depends on this company?
Myelofibrosis patients depend on JAKAFI directly — without JAK2 blockade, the bone marrow scarring that defines their disease goes untreated and progresses. Specialty oncology practices would lose their main treatment option for polycythemia vera patients. Clinical researchers running graft-versus-host disease trials where JAK inhibition is the foundation of the treatment protocol would lose their backbone therapy.
How does this company scale?
The chemistry of making ruxolitinib and other JAK inhibitors can be produced at larger volumes through standard pharmaceutical manufacturing once the process is established — that part scales normally. What does not scale with money is the clinical trial process needed to enter each new rare blood cancer indication, because those trials depend on finding enough patients with specific rare conditions, and that global pool of patients is small and fixed.
What external forces can significantly affect this company?
Medicare Part D coverage rules directly affect whether patients in the US can access and afford JAKAFI, which is an expensive specialty oral drug. In Europe, the European Medicines Agency's rules around orphan drug designation shape how long commercial exclusivity lasts for rare-disease treatments. An aging population means more people will develop myelofibrosis over time, which could expand the market — but that same aging population is also driving pressure on governments and insurers to push back on the cost of expensive specialty therapies.
Where is this company structurally vulnerable?
If a serious safety problem emerged in patients using JAKAFI for myelofibrosis or polycythemia vera, regulators could pull or restrict the drug. That would do three things at once: competitors would no longer need to beat JAKAFI's standard to win approval, doctors would have no reason to stick with it, and the revenue that funds trials for new rare-disease indications would dry up.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Multi-Year Up-Close-Week Share With Profitability And Book-Value Growth
Three observations describe the present configuration: a high share of the trailing three years' weekly closes were higher than the prior week, the company has reported positive net income in each of the last five annual periods, and the book-value-increase-consistency composite over the trailing 5 years is elevated.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
6 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three Asset-Base Ratios Elevated
Three asset-base observations have aligned: industry-benchmarked asset turnover is in the upper peer range, operating-income-to-total-assets is in the upper portion of its mapped range (scaled to 20%), and gross-profit-to-total-assets is in the upper portion of its mapped range (scaled to 50%).
Cash Backing With Revenue And Income Streaks
Three observations co-occur: the weighted composite of net cash relative to market cap, OCF/revenue, operating margin, and ROE is in its elevated range; revenue increased every year for three years; net income was positive every year for three years. The configuration describes a present-state combination of capital structure, cash generation, profitability, and top-line growth.
Industry-Benchmarked ROA and Margin Elevated
Three industry-benchmarked observations co-occur: median 5-year ROA and operating margin sit at the upper end of the industry peer range, gross margin is elevated, and return on equity is elevated. The configuration describes peer-relative profitability persistence, not a specific competitive mechanism.
Industry-Benchmarked Return on Capital Elevated
Three industry-benchmarked observations co-occur: return on equity is elevated, asset turnover is elevated, and return on assets is elevated. Because asset turnover and ROA both fire alongside ROE, the elevated ROE is not solely a leverage effect.
ROE, ROA, And Operating ROA Elevated
Three industry-benchmarked return-on-capital ratios are simultaneously in their elevated ranges: ROE, ROA, and operating ROA. Because ROA and operating ROA both fire alongside ROE, the configuration is not solely a function of equity multiplier; the underlying asset base is also producing elevated returns relative to peers.
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Three multi-year observations co-occur: revenue increased year-over-year in each of the last three fiscal years, gross profit (absolute level) increased year-over-year in each of the last four fiscal years, and net income was positive in each of the last five fiscal years. The configuration describes growth-and-profitability persistence across three different windows.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Supply Chain
Scale
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.